China Innovation Policy Reform Streamlines Trial Management
Executive Summary
China's latest initiative to establish an innovation ecosystem replaces clinical trial site pre-certification with registration; also included are provisions allowing use of foreign data, strengthening data protection and providing conditional approvals of rare disease treatments.
You may also be interested in...
China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
BeyondSpring CEO: China's New System Will Get Our Drug To Market Faster
The US/Chinese biotech expects speedier approval of its lead asset plinabulin in China thanks to the government's new drug approval policy.
Fosun Kite Bets On Cell Therapy Despite Approval Pathway Lag In China
The approval of Kite's Yescarta has ignited Chinese drug maker Fosun. With a joint venture with Kite in place, the Shanghai conglomerate is looking to accelerate CAR-T development in China despite approval pathway uncertainty.